Policy Article31 October 2026 Constructing the Unpaid Price How U.S. List Prices Are Engineered Never to Transact: The PBM Gross-to-Net Fallacy and the Emerging IRA/MFN Pricing Environment
Policy Article31 October 2026 Pricing Policy and the Modality Map: How U.S. Drug Pricing Reform Reprices Therapeutic Areas and Technology Platforms